Tag: Patent

BusinessHealthcare

Novo Nordisk’s Patent Lapse Opens Door for Generic GLP-1 Competition in Canadian Market

In a surprising regulatory development, Novo Nordisk allegedly failed to maintain patent protection for its blockbuster drug semaglutide in Canada. The oversight could enable generic competition years earlier than expected in one of the world’s largest markets for the GLP-1 medication.

Patent Maintenance Oversight Creates Generic Drug Opportunity

In what industry analysts are calling a remarkable regulatory oversight, pharmaceutical company Novo Nordisk reportedly allowed its patent for the popular diabetes and weight loss drug semaglutide to lapse in Canada by failing to pay maintenance fees, according to recent reports. The situation came to light during an interview with Sandoz CEO Richard Saynor, who revealed his company plans to launch a generic version of the GLP-1 drug in Canada as early as 2026.

by Darren Holt
BusinessEnergy

Canadian Graphene Producer HydroGraph Announces US Relocation Following Meteoric Stock Surge

HydroGraph Clean Power Inc., the Vancouver-based graphene manufacturer, is reportedly planning to relocate its corporate domicile to the United States following an extraordinary 2,000% stock price surge. The company intends to list on Nasdaq to access expanded capital markets and growing defense industry opportunities for its patented materials.

HydroGraph’s Strategic Cross-Border Move

Canadian advanced materials company HydroGraph Clean Power Inc. is planning a significant corporate relocation to the United States after experiencing a remarkable stock price appreciation exceeding 2,000% over the past year, according to recent reports. Sources indicate the Vancouver-based firm will establish its new domicile in Texas while pursuing a Nasdaq listing to tap into deeper capital markets and defense-sector demand for its specialized materials.

by Natalie Brooks